Among these, the CD44—a multifunction cell surface adhesion receptor that is expressed by prostate cancer cells—binds to vascular cell adhesion molecule 1 (VCAM-1), and other factors, including insulin-like growth factor 1 (IGF1), insulin, and interleukin-17 (IL-17) are able to boost this process [18]. Here, IL17A is linked to prostate carcinoma.